Cefquinome-loaded microsphere formulations against *Klebsiella pneumonia* infection during experimental infections

Shaoqi Qu\(^{a,b}\), Cunchun Dai\(^{a,b}\), Jiajia Zhu\(^{a,b}\), Li Zhao\(^{a,b}\), Yuwen Li\(^{a,b}\) and Zhihui Hao\(^{a,b}\)

\(^{a}\)Agricultural Bio-pharmaceutical Laboratory, Qingdao Agricultural University, Qingdao, China; \(^{b}\)National-Local Joint Engineering Laboratory, Agricultural Bio-pharmaceutical Technology, Qingdao, China

**ABSTRACT**

The aim of this study was to prepare cefquinome-loaded polylactic acid microspheres and to evaluate their *in vitro* and *in vivo* characteristics and pharmacodynamics for the therapy of pneumonia in a rat model. Microspheres were prepared using a 0.7 mm two-fluid nozzle spray drier in one step resulting in spherical and smooth microspheres of uniform size (9.8 ± 3.6 μm). The encapsulation efficiency and drug loading of cefquinome were 91.6 ± 2.6% and 18.7 ± 1.2%, respectively. *In vitro* release of cefquinome from the microspheres was sustained for 36 h. Cefquinome-loaded polylactic acid microspheres as a drug delivery system was successful for clearing experimental *Klebsiella pneumonia* lung infections. A decrease in inflammatory cells and an inhibition of inflammatory cytokines TNF-α, IL-1β and IL-8 after microspheres treatment was found. Changes in cytokine levels and types are secondary manifestations of drug bactericidal effects. Rats were considered to be microbiologically cured because the bacterial load was less than 100 CFU/g. These results also indicated that the spray-drying method of loading therapeutic drug into polylactic acid microspheres is a straightforward and safe method for lung-targeting therapy in animals.

1. **Introduction**

*Klebsiella* (*K.* pneumonia) is an opportunistic pathogen causing life-threatening nosocomial infections and one of the most frequently isolated Gram-negative bacterial pathogens. The rapidly progressive clinical course of *K. pneumonia* is often complicated by lung multilobe involvement and abscesses. The high mortality of these infections often leaves little time to initiate effective antibiotic treatment (Yoshida et al., 2001).

Current treatments for pneumonia involves the long-term oral administration of high doses of multiple drugs (Bramwell & Williams, 2009). This treatment can lead to serious side effects including liver or kidney damage. Selectivity of a drug distribution to lungs cannot be ensured by an oral route and the difficulty of delivering drugs to sites deep within the lungs, to the actual site of the infection. Targeting drug delivery system increases the drug quantity at the target site while simultaneously decreasing the distribution to other body regions (Liu et al., 2017). Lung delivery of drugs is a major clinical problem (Suarez et al., 2001; Zhou et al., 2005; Hirota et al., 2007).

Microsphere drug delivery systems (or microspheres) are an alternative to uncomplexed drug delivery and provide a slower intracellularly release of therapeutic drug doses (Liu et al., 2003). Biodegradable polymers such as polylactic acid (PLA), polylactic-glycolic acid (PLGA) and albumin have been used for microsphere encapsulation matrices and are biologically inert and nontoxic (Okada et al., 1995; Qu et al., 2017). The rate and extent of drug release from microspheres is dependent upon the particle size, extent of crosslinking as well as the physiochemical properties of the drug (Deng et al., 1999).

Spray-drying is a single step process applicable to even heat-sensitive materials (Zhang et al., 2000). This technique has a potential for the large scale encapsulation of drugs due to the use of mild conditions. Furthermore, it generally yields microparticles of a narrow size distribution that possess high encapsulation efficiencies (Palazzo et al., 2013).

Cefquinome (CEQ) is an aminothiazolyl cephalosporin and the first member of the fourth-generation cephalosporins developed for use in veterinary medicine (Kasravi et al., 2011; Xiao et al., 2013). This drug has demonstrated *in vitro* and *in vivo* efficacy against a wide range of Gram-negative and Gram-positive bacteria (Widmer et al., 2009). Pneumonia caused by *K. pneumonia* results in the recruitment and activation of leucocytes that involves coordinated expression of both pro- and anti-inflammatory cytokines (Song et al., 2004). For example, the IL-10 produced during *K. pneumonia* lung infection promotes bacterial survival. Inhibition of its anti-inflammatory properties promotes bacterial killing because pro-inflammatory cytokines such as IL-1β, IL-6 and TNF-α are allowed to be activated (Greenberger et al., 1995).

In the current study, we prepared PLA microspheres as a CEQ carrier in a single step using a 0.7 mm two-fluid nozzle spray drier and were characterized in terms of morphology, size, drug-loading coefficient, encapsulation ratio and
in vitro performance. We then evaluated the pharmacodynamics of the coupled microspheres in the lungs of rats infected with *K. pneumonia*.

## 2. Materials and methods

### 2.1. Materials

Polyactic acid (inherent viscosity 0.28 dL/g, MW 30 kDa) was produced by Shandong Institute of Medical Instruments (Jinan, China). Cefquinome injection (2.5%, wt/v) was purchased from MSD Animal Health (Dublin, Ireland). Acetonitrile (HPLC grade) was purchased from Fisher Scientific (Pittsburgh, PA, USA). Purified water was produced using a MilliQ Plus water filtration system. All other chemicals and solvents used were purchased from Sinopharm Chemical Reagent (Shanghai, China) and were of analytical grade or better.

### 2.2. Preparation of the microspheres

CEQ-loaded microspheres were prepared at the theoretical loading of 20% (20 mg of CEQ per 80 mg of polymer) by spray-drying a solution in a Lab Spray-Dryer SY-6000 (Shanghai, China). The dispersion was prepared dispersing 200 mg of CEQ powder in 50 mL methylene chloride containing 800 mg of PLA under gentle vortexing. Spray drying was performed with the following process parameters: inlet temperature, 50°C; supply rate for solution, 8 mL/min; spray-flow 700 NL/h.

### 2.3. Microsphere characterization

The morphology of the microspheres was evaluated by scanning electron microscopy (SEM; Jeol, JSM-7500F, Tokyo, Japan). Dry microspheres were mounted on carbon-taped copper stubs and sputter coated with gold for 1.5 min at 8 mA for observation.

Five hundred particles were measured for particle size distribution and measurements were carried out using SEM. The amount of CEQ encapsulated in the PLA microspheres was determined by a high-performance liquid chromatography (HPLC) method. Briefly, 50 mg of CEQ-loaded PLA microspheres were dissolved in 50 mL of methylene chloride followed by a 10-fold dilution with the HPLC mobile phase consisting of acetonitrile–water (85:15, v/v). After centrifugation at 6000×g for 10 min, the supernatant was collected and used for injection into an Agilent 1200 HPLC system (Agilent Technologies, Santa Clara, CA) to quantify CEQ. All measurements were conducted in triplicate and the results were expressed as mean ± SD.

CEQ loading was expressed as mg of encapsulated CEQ per 100 mg of microspheres. CEQ entrapment efficiency (%) was calculated as follows: amount of CEQ in microspheres / CEQ quantity added in the microsphere preparation process.

### 2.4. In vitro release study

CEQ-loaded PLA microspheres (50 mg) were dispersed into 2 mL of phosphate buffer saline (PBS) (pH 7.4) and membrane dialyzed (MW cutoff 8-14 kDa, Millipore, MA, USA) against 250 mL of PBS (pH 7.4). An identical amount of solid CEQ was used as a control. The system was agitated at 37°C ± 1°C in a shaking water bath set at 100 rpm for 48 h in the dark. At predetermined time intervals, medium was withdrawn in 2 mL volumes and replaced with an equal volume of fresh release medium. The samples were filtered and the CEQ content was determined by HPLC as described above. The release studies were performed in triplicate and the results are presented as the mean ± SD. The results of all measurements were used to calculate cumulative drug release.

## 2.5. In vivo of pharmacodynamics studies

### 2.5.1. Pneumonia model in rats

Pulmonary infection was induced in the rats as previously described (Bakker-Woudenberg et al., 1979; Kesteman et al., 2010). The trachea of each rat was cannulated under general anesthesia, and the lungs were inoculated with 0.05 mL of a saline suspension of *K. pneumonia* containing 2 × 10⁶ CFU/mL. The control rats were inoculated with saline only. The clinical status of each infected rat was recorded twice daily.

Germfree male Wistar rats (Vital River Laboratory, Beijing, China), aged 5 weeks old, at weights of 180–200 g, and were housed under specific-pathogen-free conditions, with a 12-h light/12-h dark cycle. The experiment followed the Guidelines of Experimental Animal Care issued by the Animal Welfare and Research Ethics Committee at Qingdao Agriculture University.

Rats were divided into four subgroups: (1) Control group (*n* = 30); (2) *K. pneumonia* disease (KPD) model group (*n* = 30); KPD rats were injected with physiologic saline; (3) KPD with injection group (*n* = 30); KPD rats were injected with CEQ injection (12.5 mg/kg); (4) KPD with CEQ-microspheres (*n* = 30); KPD rats were injected with 12.5 mg/kg CEQ-coupled microspheres. After the injection of bacteria for 3 days, treatment was initiated when an animal showed clinical signs of infection (coughing, close-set eyes, immobility, quilted coat, or hunched posture) (Vasseur et al., 2014) and consisted of a tail vein injection of 12.5 mg/kg of CEQ.

### 2.5.2. Preparation of bronchoalveolar lavage fluid (BALF)

At predetermined time points (0, 4, 12, 24, 48 h) after dosing, rats were anesthetized by intraperitoneal injection of chloral hydrate (300 mg/kg). Four milliliters of sterile physiologic saline was instilled three times via the tracheal cannula and recovered by gentle manual aspiration. The three lavage fractions were centrifuged at 2000×g for 10 min at 4°C, and the cell-free supernatants were stored at −70°C for subsequent cytokine analyses (Xiao et al., 2013). The cell pellet was washed twice with phosphate-buffered saline (PBS) and suspended in 1 mL of RPMI 1640 containing 10% fetal bovine serum and 1% penicillin-streptomycin solution (Gibco, Carlsbad, CA) in six-well tissue culture microplates. The plates were incubated for 2 h at 37°C in a humidified atmosphere of 5% CO₂. After the removal of supernatant, adherent cells were suspended in RPMI 1640 at a concentration of 2 × 10⁶ cells/mL for subsequent phagocytosis analyses. Cell viability
was checked with the Trypan blue dye and was >96%. Cell purity checked by the Giemsa dye test was >98%.

2.5.3. Bacterial counts
Each rat was treated with bronchoalveolar lavage and then was sacrificed in a CO2 chamber and its lungs were aseptically removed and homogenized in 10 mL of normal saline. The homogenates were centrifuged at 2500 × g for 10 min, and the pellets were suspended in 2.5 mL of normal saline. The counts of *K. pneumonia* organisms were obtained after plating serial dilutions of lung homogenates on Mueller–Hinton agar (Bio-Rad, CA, USA). The colonies were counted after 24 h of incubation at 37°C. The lowest level of detection was 100 CFU/lung, and the rats were considered to be microbiologically cured if they were found to have counts below this level (Vasseur et al., 2014).

2.5.4. Phagocytosis analyses
The uptake of the neutral red dye by macrophages was measured following the procedure of Long et al. (2005), with the following modifications. The cell suspension (2 × 10^6 cells/mL, 100 μL/well) was incubated in a 96-well flat-bottomed microtiter plate for 2 h at 37°C in a 5% CO2 atmosphere. After one wash with warm PBS (pH 7.4), 200 μL of 0.1% neutral red (Amresco, Solon, OH, USA) solution in PBS was added. To minimize crystal formation during the incubation, the dye solution was incubated overnight at 37°C and sterile filtered before use. Following 30 min of incubation of the culture plates at 37°C, the neutral red solution was aspirated, and each well was carefully rinsed three times with PBS. Finally, the intracellular dye was extracted with 200 μL of a mixture of ethanol and acetic acid (1:1 v/v). The mixtures were evaluated at a wavelength of 550 nm on a Bio-Rad 550 microplate reader (Bio-Rad, CA, USA). The absorbance represented phagocytosis by macrophages.

2.5.5. Cytokine measurement
The levels of TNF-α, IL-1β, IL-8, IL-4, IL-10 and IL-13 in the bronchial lavage supernatants were determined using the corresponding ELISA kits (Nanjing Jiancheng, China) according to the manufacturers’ instructions.

2.5.6. Histopathological analysis
After intravenous administration of CEQ microspheres to infected rats at a dose of 12.5 mg/kg CEQ, the left lungs were collected for histopathological analysis as described previously. (Kandemir et al., 2015)

2.6. Statistical analysis
Values are presented as mean ± standard deviation (SD). Data were analyzed using SPSS V 15.0 (SPSS Inc., Chicago, IL) and the differences between groups were compared with one-way ANOVA followed by Dunnett’s multiple comparison procedure and the p value < .05 was considered as statistically significant.

3. Results and discussion
CEQ is unsuitable for *in vivo* use due to its short biological half-life and toxicity (Wang et al., 2014). To alleviate these effects and give sustained delivery of therapeutic agents to the lungs, particulate delivery systems such as liposomes and polymeric nano- and micro-particles have been used (Chi et al., 2015; Zhang et al., 2015; Qu et al., 2017). Biodegradable microspheres have been extensively studied for almost half a century and encapsulation using PLA particles is a successful practice in both clinical and research settings (Khaimar et al., 2014; De Clercq et al., 2016). There are several methods for generating PLA particles including spray drying and phase separation / solvent extraction (Aubert-Poussé et al., 2004; Acharya et al., 2009). The latter method is most often used but results in single bulk batches requiring large amounts of reagents, time and labor.

We used a spray drying process to overcome these limitations. Our microspheres were globular in appearance and dispersed well (Figure 1). The particle size distribution of the coupled microspheres had mean diameters of 9.8 μm in the ranges of 10% = 4.5 μm, 50% = 9.2 μm and 90% = 15.7 μm. This result demonstrated that it is feasible to use the two-fluid nozzle spray-drying method to prepare CEQ-coupled microspheres in one step without requiring a common solvent for the water insoluble PLA, and the water-soluble CEQ. The average drug loading and encapsulation efficiencies were 18.7 ± 1.2% and 91.6 ± 2.6% (n = 3), respectively. Drug-loaded microspheres of highly water-soluble drugs like CEQ using the spray drying technique have given optimal entrapment efficiencies. This is the case because the outer aqueous phase can be rapidly removed by high-speed hot air.

When we examined *in vitro* CEQ release profiles, the microspheres showed three primary discharge processes. The first was an initial burst of CEQ from the sphere surface (up to 0.5 h). The second was a constant release stage (1–36 h) and the third was a lack of drug release from the microspheres (36–48 h) (Figure 2). Of the total CEQ in the CEQ-PLA-microspheres, 15.2% was released during the first 0.5 h. This reflected CEQ adsorbed on, or incorporated near the microsphere surfaces. In clinical practice, this process would

Figure 1. CEQ-loaded PLA microspheres observed by scanning electron microscopy.
result in rapid treatment by a rapid increase of the active ingredient concentration.

Our microspheres had a relatively low porosity and were degraded slower more than 36 h which thereby extended the release plateau (Freiberg & Zhu, 2004). After 36 h, almost all CEQ was released and this process was much slower than non-incorporated CEQ in solution (Figure 2). Therefore, the in vitro performance of the microspheres showed prolonged and sustained CEQ release.

CEQ is widely used in clinical veterinary medicine. However, long-term use of CEQ may result in serious damage to liver or kidney including acute renal failure (Du et al., 2016). Targeting CEQ directly to lung tissues would avoid possible toxic effects to other organs. The size of our microspheres was in the range required for lung targeting so we administered either CEQ-coupled microspheres or CEQ alone via i.v. injection to rats (Peppas, 1985). The concentration of CEQ in the kidney was higher than in other tissues after intravenous injection with CEQ solution in rats (Supplement Figure 1(A)). In contrast, the CEQ-PLA-microspheres delivered CEQ primarily to the lung after intravenous injection (Supplement Figure 1(B)). The microspheres showed a combination of lung-targeting and sustained drug release characteristics (Supplement Figure 1), then we conducted pharmacological researches.

Since phagocytosis and elimination of foreign agents are typical functions of macrophages, we examined the effects of CEQ-PLA-microspheres on the phagocytic activity of alveolar macrophages. Failure of this arm of the innate immune response could lead to treatment failure (Taylor et al., 2010).

The purity of alveolar macrophages exceeds in all groups were exceeding over 98%. The phagocytic activity of alveolar macrophages from the KPD rats was significantly lower than that of the control group. Since the infection itself can cause host immune damage, the bacteria impaired the phagocytic ability of the macrophages. When the rats were challenged with either CEQ-PLA-microspheres or CEQ alone, phagocytic functions were significantly greater than the control untreated and uninfected rats (Figure 3). These results indicated that the CEQ-loaded microspheres provided a successful treatment outcome.

To examine the KPD infection model more closely, we determined actual bacterial numbers in the lungs of rats from the different treatment groups. The group lacking treatment displayed a peak of bacterial numbers at 24 h post-infection. After this point, there was a downward trend and the number of bacteria remained at around $10^5$ CFU/g. The group receiving CEQ alone showed a drastic reduction on bacterial numbers as early as 4 h post-infection (Figure 4). However, the rats were not cured of the infection and was most likely due to the short half-life of the drug ($t_{1/2} = 0.85$) (Zhou et al., 2015). The group receiving the CEQ-loaded microspheres achieved a further 1 log reduction of *K. pneumonia*. After 48 h, the rats were considered to be
microbiologically cured because the bacterial load was less than 100 CFU/g (Figure 4). In conclusion, we have successfully prepared a drug-loaded microsphere delivery system for the treatment of pneumonia caused by *K. pneumonia*.

Phagocytosis of pathogens by macrophages plays an important role in immune regulation and involves the migration and adhesion of macrophages. Under the influence of chemokines, macrophages are recruited and migrate to inflammatory sites and thus exert their antibacterial effects (Cruysen et al., 1992). In our infection model we found increased levels of TNF-α, IL-1β and IL-8 after the rats had been infected with *K. pneumonia* (Figure 5(A–C), KPD model group). This indicated that *K. pneumonia* inflammation upregulated neutrophil immunomodulation by promoting the secretion of these cytokines. The peak secretion was early in infection and TNF-α, IL-1β and IL-8 reached their peaks at 24 h post-infection (Figure 5(A–C)).

![Figure 4](image)

**Figure 4.** Klebsiella pneumonia bacterial counts in lung following i.v. administration of a single 12.5 mg/kg dose of CEQ-loaded microspheres or CEQ injection. Each point represents the mean ± SD, *n* = 6. *p* < .05 compared with KPD model group. # *p* < .05 compared with CEQ injection group.

![Figure 5](image)

**Figure 5.** Cytokines in bronchoalveolar lavage fluid. The columns represent the levels of TNF-α (A), IL-1β (B), IL-8 (C), IL-4 (D), IL-10 (E) and IL-13 (F) in four groups of rats: control (no infection or drug), KPD model (infected, no drug), KPD with CEQ injection and KPD with CEQ-loaded PLA-microspheres. Results are given as mean ± SD, *n* = 6. *p* < .05, KPD with injection versus KPD model. # *p* < .05, KPD with CEQ-PLA-Ms versus KPD with injection.
These proinflammatory molecules can reciprocally stimulate inflammatory cells, including neutrophils and macrophages, to secrete more cytokines and increase phagocytic function. This process enables rapid bacterial clearance and increases lung inflammation (Zamuner et al., 2005). In the previous study, sulfated polysaccharides from *Dendrobium huoshanense* promote macrophage secretion of TNF-α, IL-6 and IL-12 that are beneficial for resisting foreign pathogen invasion (Jiao et al., 2010; Im et al., 2014; Fan et al., 2015). When bacterial numbers decrease, proinflammatory molecules return to normal levels.

In the present study, the anti-inflammatory factors in the CEQ alone and CEQ microsphere groups showed decreasing trends consistent with lower levels of bacteria (Figure 5(A–C)). At the beginning of infection, both proinflammatory and anti-inflammatory factors increased. In both these CEQ treatment groups, IL-4, IL-10 and IL-13 reached their peaks at 12 h post-infection (Figure 5(D–F)). When the bacterial numbers had declined, the anti-inflammatory factors IL-4, IL-10 and IL-13 were inhibited. This resulted in a decrease in inflammatory cells and an inhibition of inflammatory cytokines TNF-α, IL-1β and IL-8 (Figure 5(A–C)).

The start of an infection leads to secretion of proinflammatory cytokines resulting in inflammation that contributes to bacteria removal. Anti-inflammatory factors limit excessive inflammatory development and both these effects are time dependent and when not in synchrony, may result in inflammatory tissue injury. Changes in cytokine levels and types are secondary manifestations of drug bactericidal effects. Therefore, the cytokine changes in the CEQ-loaded microsphere group had the best bactericidal effects (Figure 5).

We next determined whether the curative effect of CEQ-loaded microspheres was accompanied by tissue destruction. We used the rat infection model and examined lung tissues from the treatment groups by H & E staining. There was a significant infiltration of inflammatory cells into peribronchiolar and perivascular connective tissues in non-treated infected rats. In contrast, CEQ alone and CEQ-PLA-microsphere treatments remarkably attenuated pulmonary inflammation at 12.5 mg/kg. In addition, rat lungs from the CEQ-loaded microsphere group had fewer inflammatory cells than the other group (Figure 6). Thus, the histopathological results were consistent with the bacterial count results.

4. Conclusions

This is the first report of the successful use of CEQ-PLA-microspheres as a drug delivery system for clearing experimental *K. pneumoniae* lung infections. We prepared CEQ-loaded microspheres using a spray-drying method that had physio-chemical properties and sizes suitable for *in vivo* use. This work adds to the already significant domain of targeted drug delivery systems that hold promising alternatives over conventional methods of drug delivery.

**Disclosure statement**

No potential conflict of interest was reported by the authors.
Funding
This work was supported by the National key research and development plan (NO. 2016YFD0501309) and recommend international advanced agricultural science and technology (NO.2016-X28).

References
Acharya AP, Clare-Salzer MJ, Keselowsky BG. (2009). A high-throughput microarray platform for dendritic cell-targeting vaccines. Biomaterials 30:4168–77.
Aubert-Poussel A, Venier-Julienne MC, Saulnier P, et al. (2004). Preparation of PLGA microparticles by an emulsion-extraction process using glycofurol as polymer solvent. Pharm Res 21:2384–91.
Bakker-Woudenberg IA, Jong-Hoenderop JY, Michel MF. (1979). Efficacy of conventional phagocytosis. Infect Immun 25:366–75.
Bramwell B, Williams L. (2009). Azithromycin in the treatment of pneumonic foals. Int J Pharmaceut Compound 25:382–4.
Chi L, Na MH, Jun HK, et al. (2015). Enhanced delivery of liposomes to lung tumor through targeting interleukin-4 receptor on both tumor cells and tumor endothelial cells. J Control Release 209:327–36.
Cruysen TL, Van Leengoed LA, Dekker-Nooren TC, et al. (1992). Phagocytosis and killing of Actinobacillus pleuropneumoniae by alveolar macrophages and polymorphonuclear leukocytes isolated from pigs. Infect Immun 60:4867–71.
De Clercq K, Schelfhout C, Bracke M, et al. (2016). Genipin-crosslinked gelatin microspheres as a strategy to prevent postsurgical peritoneal adhesions: in vitro and in vivo characterization. Biomaterials 96:33–46.
Deng XM, Yuan ML, Xiong CD, et al. (1999). Optimization of preparative conditions for poly-DL-lactide- polyethylene glycol microspheres with entrapped Vibrio cholerae antigens. J Control Release 58:123–31.
Du X, Zu S, Chen F, et al. (2016). Preparation and characterization of cefquinome sulfate microparticles for transdermal delivery by negative-pressure cavitation antisolvent precipitation. Powder Technol 294:429–36.
Fan L, Cui SH, Zha XQ, et al. (2015). Structure and bioactivity of a polysaccharide extracted from protocorm-like bodies of Dendrobium huoshanense. Int J Biol Macromol 72:664–72.
Freiberg S, Zhu X. (2004). Polymer microspheres for controlled drug release. Int J Pharm 282:1–18.
Greenberger MJ, Strick RM, Kunkel SL, et al. (1995). Neutralization of IL-10 increases survival in a murine model of Klebsiella pneumonia. J Immunol (Baltimore, Md.; 1950) 155:722–9.
Hirot K, Hasegaw T, Hinata H, et al. (2007). Optimum conditions for efficient phagocytosis of rifampicin-loaded PLGA microspheres by alveolar macrophages. J Control Release 119:69–76.
Im SA, Kim KH, Kim HS, et al. (2014). Processed aloe vera gel ameliorates cyclophosphamide-induced immunotoxicity. Int J Mol Sci 172:19342–54.
Jiao L, Jiang P, Zhang L, Wu M. (2010). Antitumor and immunomodulating activity of polysaccharides from Enteromorpha intestinalis. Biotechnol Bioproc Eng 15:421–8.
Kandemir F, Ozkara M, Yildirim B, et al. (2015). Rutin attenuates gentamicin-induced renal damage by reducing oxidative stress, inflammation, apoptosis, and autophagy in rats. Ren Fail 37:518–25.
Kasravi R, Bolourchi M, Farzaneh N, et al. (2011). Efficacy of conventional and extended intra-mammary treatment of persistent sub-clinical mastitis with cefquinome in lactating dairy cows. Trop Anim Health Prod 43:1203–10.
Kesteman AS, Perrin-Guyomard A, Laurentie M, et al. (2010). Emergence of resistant Klebsiella pneumoniae in the Intestinal tract during successful treatment of klebsiella pneumoniae lung infection in rats. Antimicrob Agents Ch 54:2960–4.
Khairnar G, Mokale V, Naik J. (2014). Formulation and development of nateglinide loaded sustained release ethyl cellulose microspheres by O/W solvent emulsification technique. J Pharmaceut Invest 44:411–22.
Liu SC, Pan JM, Dai XH, et al. (2017). Janus-faced and pH-responsive nanohybrids for synergistic targeted drug delivery. J Control Release 259:339–40.
Liu Z, James R, Rauth AM, et al. (2003). Delivery of an antinecancer drug and a chemosensitizer to murine breast sarcoma by intratumoral injection of sulfopropyl dextran microspheres. J Pharm Pharmacol 55:1063–73.
Long F, Wang YX, Liu L, et al. (2005). Rapid nongenomic inhibitory effects of glucocorticoids on phagocytosis and superoxide anion production by macrophages. Steroids 70:55–61.
Okada H, Hasegawa T, et al. (1995). Biodegradable microspheres in drug delivery. Crit Rev Ther Drug Carrier Syst 12:1–99.
Palazzo F, Giovagnoli S, et al. (2013). Influence of the injection site on the pharmacokinetics of cefquinome following intramuscular injection in piglets. J Vet Med Sci 440:89–92.
Palazzo F, Giovagnoli S, Schoubben P, et al. (2013). Development of a spray-drying method for the formulation of respirable microparticles containing ofloxacin-palladium complex. Int J Pharmaceut 440:273–82.
Peppas NA. (1985). Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv 60:110–11.
Qu S, Zhao L, Zhu JJ, et al. (2017). Preparation and testing of cefquinome-loaded poly lactic-co-glycolic acid microspheres for lung targeting. Drug Deliv 24:745–51.
Song H, Li GW, Ye J, Qian YS. (2004). Modulation of mouse neutrophil cytokine secretion by klebsiella pneumoniae. Comp Clin Path 13:14–18.
Suarez S, Hara P, Kazantseva M, et al. (2001). Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model. Pharmaceut Res 18:1315–19.
Taylor AE, Finney-Hayward TK, Quint JK, et al. (2010). Defective macrophage phagocytosis of bacteria in COPD. Eur Respir J 35:1039–47.
Vasseur MV, Laurentie M, Rolland JG, et al. (2014). Low or high doses of Cefquinome targeting low or high bacterial inocula cure Klebsiella pneumoniae lung infections but differentially impact the levels of antibotic resistance in fecal flora. Antimicrob Agents Chemoter 58:1744–8.
Wang WJ, Shan Q, Ding H, et al. (2014). Pharmacodynamics of cefquinome in a neutropenic mouse thigh model of Staphylococcus aureus infection. Antimicrob Agents Chemother 58:3008–12.
Widmer A, Kummer M, Eser MW, Fürst A. (2009). Comparison of the clinical efficacy of cefquinome with the combination of penicillin G and gentamicin in equine patients. Equine Vet Educ 21:430–5.
Xiao W, Chen P, Wang R, Dong J. (2013). Overload training inhibits phagocytosis and ROS generation of peritoneal macrophages: role of IGF-1 and MGF. Eur J Appl Physiol 113:117–25.
Yoshida K, Matsumoto T, Tateda K, et al. (2011). Induction of interleukin-10 and down-regulation of cytokine production by alveolar macrophages in a neutropenic mouse thigh model of Klebsiella pneumoniae capsule in mice with pulmonary infection. J Med Microbiol 50:456–61.
Zamuner S, Zuliani J, Fernandes C, et al. (2005). Inflammation induced by Bothrops asper venom: release of proinflammatory cytokines and eicosanoids, and role of adhesion molecules in leukocyte infiltration. Toxicon 46:806–13.
Zhang TY, Huang B, Wu HB, Wu JH, et al. (2015). Pharmacokinetics, bioavailability and PK/PD relationship of cefquinome with the combination of penicillin G and PK/PD relationship of cefquinome for Klebsiella pneumoniae lung infections but differentially impact the levels of anti-